Nombre del producto:methyl prop-2-ynoate

IUPAC Name:methyl prop-2-ynoate

CAS:922-67-8
Fórmula molecular:C4H4O2
Pureza:95%+
Número de catálogo:CM326338
Peso molecular:84.07

Unidad de embalaje Stock disponible Precio($) Cantidad
CM326338-250g in stock ǙľŤ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :922-67-8
Fórmula molecular:C4H4O2
Punto de fusión:-
Código de sonrisas:C#CC(OC)=O
Densidad:
Número de catálogo:CM326338
Peso molecular:84.07
Punto de ebullición:104°C at 760 mmHg
Nº Mdl:MFCD00008572
Almacenamiento:Inert atmosphere,2-8°C

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Brensocatib
May 28 2024, Insmed announced positive topline results from landmark ASPEN study of Brensocatib in patients with bronchiectasis.
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.

Related Products